Research Interests
Lily Saab received her B.S. in Chemistry with Medicinal Chemistry in 2021 from the University of St Andrews. During her final year, she conducted research on synthetic applications of the Wittig rearrangement under the guidance of Dr. Alan Aitken. In 2021, Lily joined Dr. Amy H. Newman’s Medicinal Chemistry Section in the Molecular Targets and Medication Discovery Branch. At NIDA, Lily is synthesizing bivalent ligands that target both dopamine D3 and mu opioid receptors and is evaluating their binding affinities using competitive radioligand displacement assays.
